IMF Videos Search Content For Healthcare Professional (182) Healthcare Provider (182) Series - Any - About the IMF (2) ASCO/EHA (163) ASH (230) Ask Dr. Durie (247) Black Swan Research Initiative (7) Community Workshops (33) Emerging Therapies (20) Facebook Live (21) Health Equity (16) IMF History (4) IMWG (13) Inspirational (16) Living Well with Myeloma (34) Myeloma in a Minute (19) Myeloma Made Simple (15) Myeloma University (12) NLB Webcasts (1) Patient & Family Webinar (27) Q&A (19) Recent News and Developments (4) Treatments (4) Trending Searches in Myeloma (1) Topics Clinical Trials (136) Financial Considerations (1) Frontline Therapy (34) Health Equity (10) Inspirational Stories (1) Lab & Imaging Tests (26) Lifestyle (4) Mental & Emotional Health (1) Public Policy & Advocacy (1) Recorded Webinars (2) Relapse/Refractory Myeloma (80) Research Updates (151) Symptom Management (8) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (31) High-Risk Myeloma (29) High-risk Smoldering Myeloma (13) Late Relapse (4–6 Lines of Therapy) (63) MGUS (18) Newly Diagnosed (Pre-Treatment or First Treatment) (52) Smoldering Myeloma (22) Types of Therapy Immunomodulatory drugs (IMiDs) (57) Immunotherapies (CAR T; BiTE, etc.) (60) Monoclonal antibodies (49) Proteasome inhibitors (50) Stem cell transplant (38) Steroids (21) Supportive Care (17) Year Published 2026 (7) 2025 (24) 2024 (23) 2023 (21) 2022 (34) 2021 (27) 2020 (18) 2019 (32) 2018 (30) 2017 (5) 2016 (3) 2015 (6) Trusted Voices Dr. María-Victoria Mateos (8) Dr. Saad Usmani (4) Dr. Shaji Kumar (4) Dr. Brian GM Durie (3) Dr. Joseph Mikhael (3) Dr. Sagar Lonial (1) Dr. Sigurður Kristinsson (1) Dr. Tom Martin (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel in Patients with Relapsed Refractory Multiple Myeloma December 13, 2021 ASH Monitoring of Circulating Tumor Plasma Cells (CTPC) in Patients with Precursor Conditions of Multiple Myeloma: Data from the Prospective iStopMM Study December 13, 2021 ASH REGN5458, a BCMA Bispecific Monoclonal Antibody Targeting CD3, in a Phase 1/2 1st-in-Human Study in Relapsed/Refractory Multiple Myeloma Patients December 12, 2021 ASH Adapting Clinical Practice to a Rapidly Changing Therapeutic Landscape in Multiple Myeloma December 10, 2021 ASH Clinical activity and safety of cevostamab in relapsed/refractory multiple myeloma December 15, 2020 ASH Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma December 15, 2020 ASH First Data from the Phase 1 Study of the GPRC5DxCD3 Bispecific Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma December 14, 2020 ASH Updated Results of the Idecabtagene Vicleucel (ide-cel bb2121) CRB-401 Trial in Relapsed Refractory Multiple Myeloma December 14, 2020 ASH Evaluating Teclistamab in Relapsed and/or Refractory Multiple Myeloma December 14, 2020 ASH Results of Iberdomide in Combination with Dex and Daratumumab or Bortezomib in Patients with RRMM December 12, 2020 ASH Updated Safety and Efficacy from ANCHOR Study of Melflufen in Relapsed Refractory Multiple Myeloma December 12, 2020 ASH Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial December 11, 2020 ASH Load More
